Aktiesnakken — Oktober 2009
-
læg mærke til at consensus for Genmab i 2013 nu kun er 500 mill dollar, altså kun CLL.
-
Current consensus analyst forecasts for Arzerra, which is also being developed for rheumatoid arthritis, suggests annual sales will reach
-
$560 million in 2013, according to Thomson Pharma.
-
vejen er rigtigt nok, men nu havde jeg vist ikke spået stigningen denne gang
-
jeg har haft genmab siden 2002, så jeg tror ikke du taler til mig
-
du kan jo også vente til 115.....
-
jeg ville aldrig røre b&o med en ildtang
-
ja det er jo det du siger, jeg er bare glad for at jeg fik ret på det fundamentale, så lader jeg dig styre kursen intraday
-
der må ske et eller andet bag tæppet i GEN. Det her er ikke en naturlig udvikling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind